other material
confidence high
sentiment negative
materiality 0.80
Pulse Biosciences enters $60M ATM equity facility; prelim Q2 net loss $10.7-12.7M
PULSE BIOSCIENCES, INC.
- Up to $60M at-the-market offering via Canaccord Genuity and Needham; commission up to 3%.
- Preliminary Q2 2024 cash and cash equivalents $26.0-26.5M (excl. $60M rights offering close in July).
- GAAP net loss $10.7-12.7M; non-GAAP net loss $8.7-9.7M.
- GAAP costs and expenses $11-13M; non-GAAP costs $9-10M; adjustments include stock-based comp and D&A.